Efficacy and Safety of the Anti-PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study.
Jusheng AnJie TangBenjamin X LiHuihua XiongHui QiuLin LuoLi WangDanbo WangQi ZhouQin XuHonglin SongYunyan ZhangHongping ZhangYujie LiXiaohui YuJing ZhangRachel NgWayne ZhaoMichael WongXiangrong DaiGuiling LiLing-Ying WuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Our study demonstrates that socazolimab has durable safety and efficacy for the treatment of recurrent or metastatic cervical cancer and exhibits a safety profile similar to other anti-PD-1/PD-L1 mAbs.